{"id":"romidepsin-chop","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiac arrhythmias"},{"rate":null,"effect":"Tumor lysis syndrome"}]},"_chembl":{"chemblId":"CHEMBL343448","moleculeType":"Protein","molecularWeight":"540.71"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Romidepsin is a histone deacetylase (HDAC) inhibitor that induces apoptosis in T-cell lymphomas by altering gene expression through chromatin remodeling. CHOP is a standard multi-agent chemotherapy regimen. The combination leverages romidepsin's targeted epigenetic mechanism with conventional chemotherapy to improve efficacy in lymphoid malignancies.","oneSentence":"Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:35.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"},{"name":"Cutaneous T-cell lymphoma (CTCL)"}]},"trialDetails":[{"nctId":"NCT01796002","phase":"PHASE3","title":"Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2013-01","conditions":"Peripheral T-cell Lymphoma","enrollment":421},{"nctId":"NCT01280526","phase":"PHASE1, PHASE2","title":"A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2011-01","conditions":"Peripheral T Cell Lymphoma","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Romidepsin + CHOP","genericName":"Romidepsin + CHOP","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}